The recommendations contained in this guideline are a consensus of the Alberta Genitourinary Tumour Team and are a synthesis of currently accepted approaches to management, derived from a review of relevant scientific literature. Clinicians applying these guidelines should, in consultation with the patient, use independent medical judgment in the context of individual clinical circumstances to direct care.
• The standard of care is adjuvant-immediate chemotherapy instillation post-TUR, unless the bladder is perforated with TUR or if there is a significant risk of vessico-ureteral reflux. Chemotherapy should consist of: epirubicin (100 mg/100 mL) or mitomycin C (MMC; 40 mg/40 mL weekly x 8 weeks then monthly for a year).
• If there is a recurrence, repeat TUR and consider proceeding to intravesical bacillus calmette-guerin (BCG) therapy.
Induction and Maintenance Therapy Induction and maintenance therapy is recommended for intermediate and high risk patients, including those with multifocal tumours or frequent recurrences.
• BCG: induction therapy for 4-6 weeks then 3-weekly injections at 3-month intervals; continue for 12-24 months, if patient is disease-free at three months. Therapy may be continued at 30 and 36 months, at which time a clinical decision should be made as to whether or not to proceed with maintenance.
• MMC: 40 mg/ mL monthly; continue for 12-24 months.
Second-line treatment for Ta BCG failure • Surgery consisting of aggressive TURBT is recommended.
• Intravesical chemotherapy options include:
o Interferon alpha-2b (IFN-α2b): 50 million units instillation weekly for 6-8 weeks − if residual disease at 3 months (cystoscopy): repeat with a second course at either 50 or 100 million units. − if BCG and IFN-α2b failure: 100 million units in 50 mL bladder instillation weekly for 6-8 weeks. o Gemcitabine: 2000 mg instillation weekly for 6 weeks (induction) followed by 2000 mg instillation monthly for 10 doses (maintenance) o Mytomycin C: administer intravesically at a dose of 40 mg weekly for 4 weeks o Consider cystectomy if subsequent failure occurs.
Management of Tis BCG Failure
First-line • Mandatory repeat TURBT (including muscularis propria) in 2-3 months or discussion of immediate cystectomy is recommended
In the event of an early BCG failure • Surgery is recommended, if the patient is fit.
• Radiotherapy can be considered.
• Staging: upper tract imaging (CT abdomen/pelvis with contrast) is recommended.
In the event of a late BCG failure • Surgery is recommended, if the patient is fit.
• Staging: upper tract imaging (CT abdomen/pelvis with contrast) is recommended. 
Management of T1 high grade BCG Failure

Follow-up
• Cystoscopic evaluation q 3 months for the first 24 months, then annually for 10 years • Radiological evaluation of lymph nodes and contra lateral upper tract as clinically indicated • Duration: as clinically indicated; cystoscopic evaluation and CXR as clinically indicated and then at increasing intervals
DISCUSSION
The management of Ta and T1 bladder cancer includes resection plus adjuvant-immediate chemotherapy, consisting of epirubicin or mitomycin C. 12, 13 Recurrences are common in bladder cancer 14 and management consists of bacillus calmette-guerin therapy (BCG). In intermediate to high risk patients, the addition of prulifloxacin has not been shown to improve recurrence rates at six months (21.6 vs. 23.0%); 15 however, in another study, the addition of gemcitabine to BCG therapy increased the time to recurrence by 4.3 months (24.1 vs. 19.8 months; P<.05). 16 Recently, an EORTC trial (Sylvester, et al. 2010) showed that in intermediate and high risk patients (n=820), BCG significantly reduced the rate of recurrence (36.7 versus 52.7% epirubicin; P<.05) and increased the rate of overall survival (70.1 versus 62.0%; P<.05), with a median follow-up of 110 months. 17 Another smaller study (n=89 Ta/T1 patients) showed that, after a median follow-up of 102 months, BCG resulted in a significantly lower recurrence rate versus mitomycin-C (59.1 versus 80%; P<.05); disease-free survival was also higher in patients treated with BCG (90.9 versus 80.0%). 18 A complete summary of the evidence on BCG therapy is provided in Appendix B (page 15).
For Ta disease, in the event of a failure on BCG therapy, options include salvage surgery, BCG therapy plus alpha-2b interferon, or mitomycin C. 12 Gemcitabine has also demonstrated efficacy: overall survival rate was approximately 20% higher (approximately 70 versus 50%; P<.05) versus mitomycin-C at a median follow-up of 36 months; 19 recurrence rate was 35% lower (52.5 versus 87.5%; P<.05) versus BCG; 20 and recurrence free survival rate was approximately 16% higher (19 versus 3%; P<.05) versus BCG (median follow-up of 12 months). 20 However, in a smaller study of high risk patients, BCG was more efficacious than gemcitabine, in terms of recurrence rate (28.1 versus 53.1%; P<.05). 21 Larger trials with gemcitabine are required and currently BCG plus alpha-2b interferon or mitomycin-C remains the standard of care for first-line treatment of recurrent disease.
For Tis disease, in the event of a failure on BCG therapy, and for T1 high-grade disease, BCG therapy followed by repeat TURBT or discussion of immediate cystectomy is mandatory. 12 Adjuvant therapy consists of immediate instillation with epirubicin. Maintenance therapy consists of BCG with alpha-2b interferon, if the patient is disease free at first cystoscopy. In patients with stage Ta or T1 bladder cancer (n=115) given one of the following three treatments, post-TURBT: (1) maintenance therapy with BCG (81 mg, intravesically) once weekly for 6 weeks followed by three once-weekly instillations at 3, 6, 12 and 18 months; (2) BCG (81 mg, intravesically) once weekly for 6 weeks; or (3) epirubicin (40 mg, intravesically) instilled nine times, the recurrence-free survival rates after two years of follow-up were 84.6%, 65.4%, and 27.7%, respectively. 13 Maintenance therapy with BCG is an important component of care in this setting. 
GLOSSARY OF ABBREVIATIONS
DISSEMINATION
• Present the guideline at the local and provincial tumour team meetings and weekly rounds.
• Post the guideline on the Alberta Health Services website.
• Send an electronic notification of the new guideline to all members of CancerControl Alberta.
MAINTENANCE
A formal review of the guideline will be conducted at the Alberta Genitourinary Tumour Team Annual Meeting in 2015. If critical new evidence is brought forward before that time, however, the guideline working group members will revise and update the document accordingly. 
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